JTJonas Tverring

Jonas Tverring

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jonas Tverring has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Blood culture time to positivity corrected for delayed incubation start - a population-based study

    by Karl Oldberg, Torgny Sunnerhagen, Oskar Ljungquist, Magnus Rasmussen, Jonas Tverring, Gustav Torisson

    Purpose: A short blood culture time to positivity (TTP) is associated with an increased risk for death in blood stream infections (BSI). However, TTP is also shortened when the time elapsed from sampling to incubation start (TTI) increases. We aimed to test whether TTP corrected for TTI was more strongly associated with 7-day mortality in BSI. Methods: This was a retrospective analysis of positive blood culture bottles in Skåne region, Sweden, 2015 to 2023, with linked clinical data obtained from healthcare databases. Correction factors were derived using linear regression between TTI and TTP. The association between TTP and 7-day mortality was studied in BSI episodes, using non-linear logistic regression. Actual mortality rates and odds ratios (OR) for different TTP cutoffs were calculated. Results: In total, 100,829 bottles were included and each hour of TTI was associated with a shortening of TTP by 0.27 h in aerobic bottles and 0.32 h in anaerobic bottles. After deduplication, 31,723 unique BSI episodes were included in mortality analysis, with a 7-day mortality rate of 6.4%. In non-linear regression models, corrected TTP showed a stronger association with 7-day mortality than crude TTP in episodes with TTP < 10 h. Actual mortality rates were higher for corrected TTP at all cutoffs between 6 and 12 h. Conclusion: TTP corrected for TTI was more strongly associated with 7-day mortality than crude TTP. We recommend that correction for TTI should be used in future studies on TTP, especially if on-site incubation is unavailable.

  • Open Access

    Addressing infection in totally implantable venous access ports: An ex vivo study on bacterial transfer and the Forsvall Port needle design

    by Håkan Pärsson, Magnus Wagenius, Maria Utter, Jonas Tverring, José Francisco Pereira Cardoso, Andreas Forsvall

    Background: Totally implantable venous access ports (TIVAPs) are essential for administering chemotherapeutic drugs and nutritional support, but carry a risk of infectious complications. We hypothesized that the design of the current port needle (Huber) could facilitate the collection of bacteria from the skin during puncture, potentially introducing them into TIVAPs and causing infections. This study examines bacterial transfer via needles during TIVAP access and proposes a novel needle design to reduce the risk of infection. Methods: A novel needle, the Forsvall Port needle, was developed with a closed tip to reduce bacterial transmission inside the needle during tissue and port penetration. In a randomized ex vivo setting, human skin samples covered in physiological levels of Staphylococcus aureus were placed over port membranes and punctured repeatedly by the standard Huber needle and the Forsvall Port needle. Cultures from the needle tips were plated after puncture and used to compare bacterial transfer into TIVAPs using a generalized linear mixed-effects model. Punctures were performed in a separate human skin to examine the mechanism of bacterial transfer. Results: The Forsvall Port needle reduced average bacterial transfer by 87.0% (95% CI: 77.8%–92.4%, p < 0.0001) compared with the Huber needle, based on 10 punctures per needle across four skin samples. Additional testing on a separate skin sample showed that a defectively fitted Forsvall Port needle prototype did not reduce bacterial transfer relative to the Huber needle (95% CI: 58.3% decrease to 30.0% increase, p = 0.289), whereas a steel rod simulating a perfectly closed Forsvall Port needle achieved a 99.9% (95% CI: 99.5%–100%, p < 0.0001) reduction in bacterial transfer. Conclusion: The Forsvall Port needle significantly reduces bacterial transfer into TIVAPs, which could potentially decrease TIVAP-related infections. This study demonstrates a strong association between needle design and bacterial transfer during TIVAP access.

  • Open Access

    Septic arthritis score (SAS) – a novel clinical prediction model for the probability of septic arthritis in the adult native knee

    by Jonas Tverring, Amelia Johansson, Omid Bornaei, Adam Lantz, Oskar Ljungquist

    Background: Patients presenting with an acutely painful swollen joint represent a diagnostic challenge. We aimed to develop a clinical prediction model for septic arthritis (SA) in the adult native knee. Methods: We screened all synovial cultures in south Sweden in 2020 and 2021. We included cultures taken in the emergency department from adults’ native knees where SA was considered a differential diagnosis based on medical chart review. We developed a prediction model using logistic regression and performed internal validation using bootstrapping. We present a nomogram and an online calculator (http://sascore.org) for individual risk estimation, net benefit compared to usual care and treatment threshold recommendations. Results: A total of 668 patients were included from 2996 screened synovial cultures. The final septic arthritis score (SAS) included four variables: synovial-to-serum glucose quotient, synovial white blood cell count, abnormal synovial fluid appearance on visual inspection, and triage priority according to Rapid Emergency Triage and Treatment System (RETTS) vital signs. SAS had an optimism-adjusted area under the receiver operating characteristics curve of 0.971 (95% bootstrap confidence interval: 0.957 to 0.987). Clinicians provided empirical intravenous antibiotics to 47 out of 51 patients with a final diagnosis of SA and to 244 out of 617 patients without SA (92% sensitivity, 60% specificity). SAS had 92% sensitivity and 92% specificity at 10% probability for SA treatment threshold and 100% sensitivity and 79% specificity at 2% treatment threshold. Conclusion: The use of SAS would theoretically avoid 50–82% of unnecessary empirical antibiotics as compared to usual care in our cohort with retained or improved identification of actual septic arthritis of the native knee. External validation is warranted before clinical use.


  • Open Access

    Diagnostic Performance of Clinical and Routine Laboratory Data in Acute Mesenteric Arterial Occlusion—An International Multicenter Study

    by Yasmin Soltanzadeh-Naderi, Annika Reintam Blaser, Martin Björck, Alexandre Nuzzo, Joel Starkopf, Alastair Forbes, Marko Murruste, Kadri Tamme, Peep Talving, Anna-Liisa Voomets, et al.

    Background: There are no clinical or laboratory markers that can diagnose acute mesenteric ischemia (AMI) accurately. This study aimed to find differences in clinical and laboratory markers between arterial occlusive AMI and other acute abdominal diseases where AMI was initially suspected. Methods: This was a post hoc study of an international prospective multicenter study where data on patients with suspected AMI were collected. Independent factors associated with arterial occlusive AMI were evaluated in a multivariable logistic regression analysis. Results: The number of patients with arterial occlusive AMI was 231, consisting of thrombotic (n = 104), embolic (n = 61), and indeterminate (n = 66) occlusions. The non-AMI group included 287 patients, of whom 128 had strangulated bowel obstruction. Current smoking (odds ratio [OR] 2.56, 95% confidence interval [CI] 1.31–5.03), hypertension (OR 2.08, 95% CI 1.09–3.97), bowel emptying (OR 3.25, 95% CI 1.59–6.63), and leukocytosis (OR 1.54, 95% CI 1.14–2.08) at admission were independently associated with arterial occlusive AMI compared to the non-AMI group. Conclusions: This study found clinical and laboratory data to be associated with arterial occlusive AMI in patients with suspicion of AMI, which can possibly be of value in screening for arterial occlusive AMI at the emergency department. Further studies are needed to find more accurate diagnostic markers.


  • Open Access

    Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI)

    by Jonas Tverring, Emeli Månsson, Vigith Andrews, Oskar Ljungquist

    Background: Oral treatment alternatives for febrile urinary tract infections are limited in the era of increasing antimicrobial resistance. We aim to evaluate if the combination of pivmecillinam and amoxicillin/clavulanic acid is non-inferior to current alternatives for step-down therapy in adult patients with febrile urinary tract infection. Methods: We plan to perform an investigator-initiated non-inferiority trial. Adult hospitalised patients treated with 1–5 days of intravenous antibiotics for acute febrile urinary tract infection caused by extended spectrum beta-lactamase (ESBL) producing Enterobacterales will be randomised 1:1 to either control (7–10 days of either oral ciprofloxacin 500 mg twice daily or oral trimethoprim–sulfamethoxazole 800 mg/160 mg twice daily or intravenous ertapenem 1 g once daily, depending on sex, drug allergy, glomerular filtration rate and susceptibility testing) or intervention (10 days of pivmecillinam 400 mg three times daily and amoxicillin/clavulanic acid 500/125 mg three times daily). The primary outcome will be clinical cure 10 days (+/− 2 days) after antibiotic treatment completion. Clinical cure is defined as being alive with absence of fever and return to non-infected baseline of urinary tract symptoms without additional antibiotic treatment or re-hospitalisation (for urinary tract infection) based on a centralised allocation-blinded structured telephone interview. We plan to recruit 330 patients to achieve 90% power based on a sample size simulation analysis using a two-group comparison, one-sided alpha of 2.5%, an absolute non-inferiority margin of 10% and expecting 93% clinical cure rate and 10% loss to follow-up. The primary endpoint will be analysed using generalised estimated equations and reported as risk difference for both intention-to-treat and per protocol populations. Patients are planned to be recruited from at least 10 centres in Sweden from 2023 to 2026. Discussion: If the combination of pivmecillinam and amoxicillin/clavulanic acid is found to be non-inferior to the control drugs there are potential benefits in terms of tolerability, frequency of interactions, outpatient treatment, side effects, nosocomial infections and drive for further antimicrobial resistance compared to existing drugs. Trial registration: NCT05224401. Registered on February 4, 2022


  • Open Access

    Pivmecillinam with Amoxicillin/Clavulanic acid as Step Down Oral Therapy in Febrile Urinary Tract Infections Caused by ESBL-producing Enterobacterales (PACUTI)

    by Jonas Tverring, Emeli Månsson, Vigith Andrews, Oskar Ljungquist

    · Background: Oral treatment alternatives for febrile urinary tract infections are limited in the era of increasing antimicrobial resistance. We aim to evaluate if the combination of pivmecillinam and amoxicillin/clavulanic acid is non-inferior to current alternatives for step-down therapy in adult patients with febrile urinary tract infection. · Methods: We plan to perform an investigator-initiated non-inferiority trial. Adult hospitalised patients treated with 1-5 days of intravenous antibiotics for acute febrile urinary tract infection caused by extended spectrum beta-lactamase (ESBL) producing Enterobacterales will be randomised 1:1 to either control (7-10 days of either oral ciprofloxacin 500mg twice daily or oral trimethoprim-sulfamethoxazole 800mg/160mg twice daily or intravenous ertapenem 1g once daily, depending on sex, drug allergy, glomerular filtration rate and susceptibility testing) or intervention (10 days of pivmecillinam 400mg three times daily and amoxicillin/clavulanic acid 500/125mg three times daily). The primary outcome will be clinical cure 10 days (+/- 2 days) after antibiotic treatment completion. Clinical cure is defined as being alive with absence of fever and return to non-infected baseline of urinary tract symptoms without additional antibiotic treatment or re-hospitalisation based on a centralised allocation-blinded structured telephone interview. We plan to recruit 330 patients to achieve 90% power based on a sample size simulation analysis using a one-sided alpha of 2.5%, an absolute noninferiority margin of 10% and expecting 93% clinical cure rate and 10% loss to follow-up. The primary endpoint will be analysed using generalized estimated equations and reported as risk difference for both intention-to-treat and per protocol populations. Patients are planned to be recruited from at least 10 centres in Sweden from 2023 to 2026. · Discussion: If the combination of pivmecillinam and amoxicillin/clavulanic acid is found to be non-inferior to the control drugs there are potential benefits in terms of tolerability, frequency of interactions, out-patient treatment, side effects, nosocomial infections and drive for further antimicrobial resistance compared to existing drugs. · Trial registration: NCT05224401

  • Open Access

    Evaluation of the Forsvall biopsy needle in anex vivomodel of transrectal prostate biopsy – a novel needle design with the objective to reduce the risk of post-biopsy infection

    by Andreas Forsvall, Jane Fisher, José Francisco Pereira Cardoso, Magnus Wagenius, Jonas Tverring, Bo Nilson, Andreas Dahlin, Ola Bratt, Adam Linder, Tirthankar Mohanty

    Transrectal prostate biopsy (TRbx) transfers colonic bacteria into prostatic tissue, potentially causing infectious complications, including sepsis. Our objective was to determine whether biopsy ne...


  • Open Access

    Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET)

    by Jonas Tverring, Anna Åkesson, Niklas Nielsen

    Background: Patients with COVID-19 and hypoxaemia despite conventional low-flow oxygen therapy are often treated with high-flow nasal cannula (HFNC) in line with international guidelines. Oxygen delivery by helmet continuous positive airway pressure (CPAP) is a feasible option that enables a higher positive end-expiratory pressure (PEEP) and may theoretically reduce the need for intubation compared to HFNC but direct comparative evidence is lacking. Methods: We plan to perform an investigator-initiated, pragmatic, randomised trial at an intermediate-level COVID-19 cohort ward in Helsingborg Hospital, southern Sweden. We have estimated a required sample size of 120 patients randomised 1:1 to HFNC or Helmet CPAP to achieve 90% power to detect superiority at a 0.05 significance level regarding the primary outcome of ventilator free days (VFD) within 28 days using a Mann-Whitney U test. Patient recruitment is planned to being June 2020 and be completed in the first half of 2021. Discussion: We hypothesise that the use of Helmet CPAP will reduce the need for invasive mechanical ventilation compared to the use of HFNC without having a negative effect on survival. This could have important implications during the current COVID-19 epidemic. Trial registration: ClinicalTrials.gov NCT04395807. Registered on 20 May 2020